Özlem Türeci
#115,559
Most Influential Person Now
German physician, scientist and entrepreneur
Özlem Türeci's AcademicInfluence.com Rankings
Özlem Türeciphilosophy Degrees
Philosophy
#6932
World Rank
#10058
Historical Rank
Logic
#4089
World Rank
#5338
Historical Rank
Özlem Türecibiology Degrees
Biology
#8502
World Rank
#11593
Historical Rank
Immunology
#536
World Rank
#553
Historical Rank
Download Badge
Philosophy Biology
Özlem Türeci's Degrees
- Doctorate Medicine University of Cologne
- PhD Immunology University of Cologne
Why Is Özlem Türeci Influential?
(Suggest an Edit or Addition)According to Wikipedia, Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards.
Özlem Türeci's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) (7900)
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) (1707)
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer (2017) (1500)
- A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. (1997) (1278)
- mRNA-based therapeutics — developing a new class of drugs (2014) (1163)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) (1143)
- Human neoplasms elicit multiple specific immune responses in the autologous host. (1995) (1115)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (1069)
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy (2016) (1020)
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer (2015) (895)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) (727)
- Exploiting the mutanome for tumor vaccination. (2012) (668)
- Personalized vaccines for cancer immunotherapy (2018) (541)
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) (527)
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera (2021) (484)
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) (413)
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. (2006) (413)
- Characterization of human colon cancer antigens recognized by autologous antibodies (1998) (354)
- Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. (1998) (350)
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2 (2021) (339)
- Serological identification of human tumor antigens. (1997) (336)
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma (2020) (332)
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2021) (290)
- Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. (1998) (287)
- The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. (1996) (272)
- SSX: A multigene family with several members transcribed in normal testis and human cancer (1997) (250)
- Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. (2010) (246)
- Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease* (1997) (243)
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma (2014) (242)
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (2021) (240)
- Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) (238)
- Serological analysis of human tumor antigens: molecular definition and implications. (1997) (233)
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure (2007) (220)
- Expression of SSX genes in human tumors (1998) (192)
- An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors (2020) (190)
- HLA typing from RNA-Seq sequence reads (2012) (189)
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development (2008) (187)
- Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo (2010) (168)
- A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis (2021) (159)
- BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans (2020) (154)
- Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. (2000) (152)
- The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
- Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation (2011) (146)
- Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies (1998) (136)
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. (2019) (135)
- Expression of the Membrane-associated Carbonic Anhydrase Isozyme XII in the Human Kidney and Renal Tumors (2000) (135)
- Elimination of large tumors in mice by mRNA-encoded bispecific antibodies (2017) (132)
- Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. (2002) (128)
- Tumor vaccination using messenger RNA: prospects of a future therapy. (2011) (124)
- Expression of cancer testis genes in human brain tumors. (2000) (123)
- A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates (2020) (113)
- Characterization of DP103, a Novel DEAD Box Protein That Binds to the Epstein-Barr Virus Nuclear Proteins EBNA2 and EBNA3C* (1999) (111)
- Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals1 (2008) (105)
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma. (2021) (99)
- Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines (2016) (99)
- A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. (2007) (96)
- Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. (2013) (96)
- Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine (2022) (95)
- mRNA therapeutics in cancer immunotherapy (2021) (92)
- Cascades of transcriptional induction during dendritic cell maturation revealed by genome‐wide expression analysis (2003) (91)
- Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. (2000) (91)
- Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study (2021) (87)
- Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020) (86)
- Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. (2006) (79)
- Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes (2022) (77)
- Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1α (2011) (75)
- Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer (2014) (69)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study (2019) (68)
- MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. (2008) (67)
- A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. (2020) (67)
- FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. (2011) (66)
- Identification of neoantigens for individualized therapeutic cancer vaccines (2022) (66)
- mRNA as a versatile tool for exogenous protein expression. (2012) (62)
- Correction: Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals (2012) (60)
- The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines (2022) (60)
- A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing (2002) (60)
- Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. (2015) (58)
- ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions (2006) (58)
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. (2018) (58)
- FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma (2016) (56)
- Mutanome directed cancer immunotherapy. (2016) (56)
- Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms (2014) (55)
- A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. (2011) (55)
- Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice (2016) (54)
- Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer (2004) (53)
- Targeting the tumor mutanome for personalized vaccination therapy (2012) (53)
- Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. (2011) (51)
- Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. (1999) (50)
- Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. (2011) (49)
- Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer (2006) (48)
- Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA (2007) (45)
- Computational dissection of tissue contamination for identification of colon cancer‐specific expression profiles (2003) (42)
- Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. (2019) (40)
- Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. (2006) (40)
- Expression of serologically identified tumor antigens in acute leukemias. (2003) (40)
- mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA (2013) (40)
- ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. (2006) (39)
- CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer (2015) (39)
- HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory (2019) (38)
- Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma (2019) (38)
- Mutated tumor alleles are expressed according to their DNA frequency (2014) (37)
- Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein β (C/EBPβ) Isoform 2* (2009) (36)
- Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins (2017) (36)
- Genomic response of the rat brain to global ischemia and reperfusion (2009) (36)
- Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside (2014) (36)
- Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6 (2015) (35)
- cDNA cloning and chromosomal mapping of a predicted coiled-coil proline-rich protein immunogenic in meningioma patients. (1997) (34)
- Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics (2011) (34)
- Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes (2014) (33)
- Identification of tumor-associated autoantigens with SEREX. (2005) (33)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. (2019) (31)
- Confidence-based Somatic Mutation Evaluation and Prioritization (2012) (31)
- Molecular Characterization of Virus-induced Autoantibody Responses (2004) (31)
- Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity. (2012) (29)
- The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. (2006) (29)
- Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2 (2009) (27)
- NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells (2013) (26)
- Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2021) (25)
- Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination (2015) (25)
- Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells. (2002) (24)
- Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adeno (2016) (24)
- Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5 (2022) (24)
- SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. (2003) (24)
- Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial. (2019) (22)
- Challenges towards the realization of individualized cancer vaccines (2018) (22)
- Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide (2018) (22)
- A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice (2020) (22)
- rapmad: Robust analysis of peptide microarray data (2011) (21)
- The European Regulatory Environment of RNA-Based Vaccines. (2017) (20)
- BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2 (2020) (19)
- Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial (2021) (19)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (19)
- Molecular characterization of virus-induced autoantibody responses. (2004) (18)
- Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. (2013) (18)
- A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes. (2009) (17)
- Autoimmunity seen through the SEREX-scope. (2003) (17)
- Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors (2020) (16)
- CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein. (2004) (15)
- Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). (2015) (15)
- First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part. (2015) (15)
- Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. (2013) (15)
- Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response (2019) (14)
- Rapid molecular dissection of viral and bacterial immunomes (2006) (14)
- Dexamethasone premedication suppresses vaccine-induced immune responses against cancer (2020) (14)
- Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years (2023) (12)
- 636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY. (2014) (12)
- 88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer (2020) (12)
- IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. (2015) (11)
- Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors (2022) (11)
- Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer (2015) (11)
- T-cell receptor transfer into human T cells with ecotropic retroviral vectors (2014) (10)
- A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo (2019) (10)
- Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma (2021) (10)
- Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors (2020) (9)
- Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma (2018) (9)
- 378PPreclinical characterization of IMAB362 for the treatment of gastric carcinoma (2017) (9)
- Targeting the tumor vasculature with engineered cystine-knot miniproteins (2020) (8)
- Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. (2017) (8)
- Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence (2017) (8)
- Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. (1997) (8)
- FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. (2016) (7)
- Antigen identification using SEREX. (2013) (7)
- Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice (2022) (7)
- Recognition of human tumors: SEREX expression cloning to identify tumour antigens (2001) (6)
- 49PA first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy (2017) (6)
- Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation (2022) (6)
- Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T-cell recognition epitopes (2022) (6)
- 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine (2021) (6)
- Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer (2021) (6)
- Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity (2016) (6)
- A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma. (2020) (6)
- Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study. (2017) (5)
- Personalized Neo-Epitope Vaccines for Cancer Treatment. (2020) (5)
- Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. (2014) (5)
- A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma. (2018) (5)
- PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation (2020) (5)
- Clinical development and approval of COVID-19 vaccines (2022) (5)
- 376PPreclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma (2017) (4)
- First report demonstrating the safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, observer-blind Phase I study (2021) (4)
- 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors (2020) (4)
- 6OIVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma (2017) (4)
- Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies (2017) (3)
- Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors. (2016) (3)
- An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation (2022) (3)
- 421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT (2021) (3)
- DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity (2022) (3)
- Health-related quality-of-life (HRQoL) results from the FAST study: A phase II trial of epirubicin, oxaliplatin, and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma. (2018) (3)
- Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC) (2019) (3)
- Abstract 882: The anti-claudin 6 antibody, IMAB027, induces antibody-dependent cellular and complement-dependent cytotoxicity in claudin 6-expressing cancer cells (2018) (3)
- 377PPreclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate (2017) (3)
- Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction (2014) (3)
- Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial (2022) (2)
- Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice (2022) (2)
- Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). (2018) (2)
- Characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice by DNA fingerprinting. (1990) (2)
- LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors (2021) (2)
- Liposome-Encapsulated Adjuvants are Potent Inducers of Antigen- Specific T-Cells in Vivo (2008) (2)
- 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation (2020) (2)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (2)
- Antibody Therapy in Oncology (2014) (2)
- Addressing COVID-19 vaccine hesitancy (2022) (2)
- Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies (2015) (2)
- 549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion (2021) (2)
- Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors (2022) (2)
- LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours (2022) (2)
- LBA-06IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer (2016) (2)
- Abstract A37: Ectopic claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer. (2014) (1)
- The role of NFATc1 in tumor T cell responses to lung cancer (101.6) (2010) (1)
- Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial (2016) (1)
- In silico strategy for detection of target candidates for antibody therapy of solid tumors. (2008) (1)
- Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age (2023) (1)
- Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA). (2018) (1)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) (1)
- Identification of Human Tumor Antigens Using the B-Cell Repertoire (1998) (1)
- 99TiPMutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (2017) (1)
- A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination (2022) (1)
- HLA typing from RNA-Seq sequence reads (2012) (1)
- Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial (2022) (1)
- Abstract LB-383: An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors (2020) (1)
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma (2014) (1)
- High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer. (2017) (1)
- A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01). (2014) (1)
- Abstract 1907: Claudin 6 is a carcinoembryonic antigen with cancer stem cell marker features (2018) (1)
- 664PPhase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer (2017) (1)
- P2.06 Exploiting The Mutanome for Tumor Vaccination (2012) (1)
- Epidemiological study of p53 tumor suppressor gene mutations in patients from Luxembourg and the German Saar region with an advanced colorectal cancer using PCR-SSCP analysis. (1998) (1)
- 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT (2022) (1)
- Targeting the tumor vasculature with engineered cystine-knot miniproteins (2020) (0)
- The role of transforming growth factor-beta signaling in a murine model of lung cancer (2009) (0)
- Monoclonal antibodies to claudin-18 for the treatment of cancer (2006) (0)
- Exploiting the Mutanome for Personalized Cancer Immunotherapy (2015) (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old (2023) (0)
- NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells (2013) (0)
- Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer (2023) (0)
- Identifying surface-associated antigens for diagnosis and tumor therapy (2006) (0)
- Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors (2023) (0)
- Under Adverse Conditions Integrin Fibronectin Receptor Promotes Tumor Cell Survival 1 β 5 α ERBB 2-Mediated Transcriptional Up-regulation of the Updated (2006) (0)
- MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors (2021) (0)
- 175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors (2022) (0)
- The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection (2023) (0)
- 1208 DuoBody®-PD-L1x4–1BB (GEN1046) reverses T-cell exhaustionin vitro (2022) (0)
- Racing for a SARS‐CoV‐2 vaccine (2021) (0)
- PO-516 E6/E7 RNA(LIP): a novel liposomal RNA vaccine for treatment of patients with HPV16-positive malignancies (2018) (0)
- Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches (2006) (0)
- Monoclonal antibodies to gt468 for treating cancer (2008) (0)
- Cancer/testis antigens in cutaneous T cell lymphomas. (2001) (0)
- 866 A Highly Specific Cancer Target, Regulated Via Promoter Methylation (2012) (0)
- Monoclonal antibodies against claudin-18 for cancer treatment (2006) (0)
- A method to detect the presence of cancer in a sample to be determined by detection of the expression of a SSX-2 gene and peptide thereof (1999) (0)
- Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2021) (0)
- Anti-GT468 monoclonal antibodies for cancer treatment (2009) (0)
- Identification of cell surface antigens associated with tumor diagnosis and therapy for (2004) (0)
- P Phase 1 Study of IMAB 362 with immunomodulation in patients with advanced gastric cancer (2017) (0)
- Abstract 763: PLAC1 interacts with FGF7 and promotes phosphorylation of FGFR2 and AKT (2018) (0)
- Challenges towards the realization of individualized cancer vaccines (2018) (0)
- Abstract 3281: GEN1042 (DuoBody-CD40x4-1BB)®in combination with PD-1 blockade reverses T-cell exhaustion in vitro (2023) (0)
- Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms (2016) (0)
- Abstract 3283: GEN1046 (DuoBody®-PD-L1x4-1BB) in combination with PD-1 blockade potentiates anti-tumor immunity (2023) (0)
- 660PFirst-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer (2017) (0)
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma (2020) (0)
- Cancer-associated nucleic acid and proteins (1998) (0)
- Imaging Immune activation by FDG PET/CT after systemic cancer vaccination therapy (2020) (0)
- Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial (2022) (0)
- 493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors (2021) (0)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (0)
- Abstract 1846: DuoBody-CD40×4-1BB (GEN1042) induces dendritic-cell maturation and enhances T-cell activation and effector functionsin vitroby conditional CD40 and 4-1BB agonist activity (2021) (0)
- 1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer (2022) (0)
- The role of transforming growth factor-beta signaling in a murine model of lung cancer (88.16) (2009) (0)
- Cancer vaccines and immunotherapy: Serologically identified tumour antigens as cancer vaccines (2000) (0)
- Multiple specific immunogenicity of human cancers in tge autologous host (2007) (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older (2022) (0)
- Abstract 1778: Preclinical characterization of the safety and antitumor activity of IMAB027-vcMMAE, an anticlaudin 6 antibody-drug conjugate (2018) (0)
- Identifying surface-associated antigens for tumor diagnosis and therapy (2003) (0)
- efficacy and T-cell stimulatory capacity of dendritic cells Modification of antigen encoding RNA increases stability, translational (2013) (0)
- Monoclonal antibodies against GT468 for treating cancer (2008) (0)
- 516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial (2021) (0)
- Recombinant vaccines and their use (2003) (0)
- Isolated MHC class II-binding peptide, and their use (2000) (0)
- Abstract B62: Evaluation of systemic RNA-based cancer vaccine induced T-cell responses via mouse T-cell receptor (TCR) profiling (2020) (0)
- Author's response to reviews Title:NCOA3 is a selective co-activator of estrogen receptor alpha - mediated transactivation of PLAC1 in MCF-7 breast cancer cells Authors: (2013) (0)
- Cancer esearch oenvironment and Immunology anodal Vaccination with Naked Antigen-Encoding RNA its Potent Prophylactic and Therapeutic R itumoral Immunity (2010) (0)
- mRNA therapeutics in cancer immunotherapy (2021) (0)
- Protective role of T-bet in anti-IL17A treatment of lung cancer (48.13) (2011) (0)
- Monoclonal antibodies to claudin-18 for treating cancer (2006) (0)
This paper list is powered by the following services:
Other Resources About Özlem Türeci
What Schools Are Affiliated With Özlem Türeci?
Özlem Türeci is affiliated with the following schools:
